How Long Do Mounjaro’s Side Effects Last?
Last reviewed: [March 2026]
Patient Guide
Medical knowledge evolves. This content is reviewed and updated periodically, but it may not always reflect the most recent research or regulatory changes. It is intended to complement — not replace — personalised medical advice from a qualified clinician.
Mounjaro (tirzepatide) is a prescription injection used to treat type 2 diabetes and support weight loss. It is given once a week and works by mimicking two gut hormones—GLP-1 and GIP—that regulate appetite, digestion and blood sugar. [1,3] Mounjaro was approved in the UK by the MHRA in September 2022 for type 2 diabetes, and its licence was extended in November 2023 to include weight management. [1,2]
Most people who take Mounjaro will experience some side effects, particularly during the first few weeks and after each dose increase. The good news is that these side effects are usually mild, are concentrated in the digestive system, and tend to ease as the body adjusts. This article explains what to expect, how long each phase typically lasts, and what you can do to reduce discomfort.
What Is Mounjaro?
Mounjaro’s active ingredient is tirzepatide, a dual GIP/GLP-1 receptor agonist. That means it mimics two hormones—glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)—that your body naturally releases after eating. This dual action is what distinguishes Mounjaro from older drugs in the same broad class, such as Ozempic and Wegovy, which target only the GLP-1 receptor. [3]
In the UK, Mounjaro is licensed for adults with type 2 diabetes. [1] It is used alongside diet and exercise to help control blood sugar. The same drug, under the same brand name, is also licensed for weight management in adults with obesity (BMI of 30 or above) or with overweight (BMI of 27 or above) and at least one weight-related condition. [2] In the US, the weight-management version is marketed under the separate brand name Zepbound, but in the UK both indications use the Mounjaro name. [1,2] Many people prescribed Mounjaro for diabetes also experience significant weight loss.
Why Mounjaro Causes Side Effects
Mounjaro’s side effects are largely a consequence of how it works. By activating GLP-1 and GIP receptors, tirzepatide slows gastric emptying—the rate at which food leaves the stomach. [3] This delay is part of the reason the drug reduces appetite and helps control blood sugar, but it also means food sits in the stomach longer than usual, which can cause nausea, bloating and discomfort.
The drug also amplifies satiety signals sent from the gut to the brain, which suppresses appetite. [3] This is a desired effect for weight loss, but when it is new to the body, it can feel like a persistent loss of appetite or mild queasiness. Blood sugar regulation is also affected: tirzepatide increases insulin release in response to meals and reduces the liver’s release of stored glucose. [3]
Most of these effects are strongest when the drug is first introduced or when the dose is increased, because the body has not yet adapted to the new level of hormonal signalling. [6]
Common Side Effects of Mounjaro
In clinical trials, the most frequently reported side effects were gastrointestinal. The rates below are drawn from the SURPASS and SURMOUNT trial programmes, which studied tirzepatide in thousands of participants: [4,5]
Nausea was the single most common side effect, reported by roughly 12–20% of participants depending on dose. It was typically mild to moderate. [1,4,5]
Diarrhoea affected approximately 12–17% of participants. Like nausea, it was most common during the early weeks and after dose increases. [4,5]
Vomiting occurred in about 5–9% of participants and followed a similar pattern, peaking early and declining over time. [4,5]
Constipation was reported by 6–8% of participants. It is related to the slowing of digestion. [1,4]
Decreased appetite was reported by 5–11% of participants. While this is one of the drug’s intended effects for weight management, some people find the reduction in hunger uncomfortable. [4]
Dyspepsia and abdominal pain (stomach discomfort, indigestion) were each reported in roughly 5–8% of participants. [4]
Fatigue and lethargy are listed as side effects in Mounjaro’s prescribing information. [1] They were reported uncommonly in clinical trials. As with many of the gastrointestinal side effects, tiredness may be partly related to reduced food intake or nausea.
Injection site reactions such as redness, itching or mild pain at the injection site were reported in approximately 3–5% of participants. These typically resolve within a day or two. [4]
Gastrointestinal side effects were dose-dependent: they were more common at higher doses. In the pooled placebo-controlled trials, the overall rate of GI side effects was about 37% at 5 mg, 40% at 10 mg and 44% at 15 mg, compared with about 20% on placebo. [1]
How Long Do Mounjaro Side Effects Last?
Most side effects follow a predictable pattern. In the clinical trials, the majority of nausea, vomiting and diarrhoea occurred during the dose-escalation phase — the period when the dose is being gradually increased — and decreased over time. [6]
The first 48 hours:
Nausea and general digestive discomfort typically onset within the first 24–48 hours after the initial injection. [7] Some people also experience a noticeable drop in appetite.
The first week:
Digestive symptoms typically persist through much of the first week but often start to stabilise towards the end of it. [7] Appetite suppression usually becomes apparent during this period.
Weeks 2–4:
The body begins to adapt. Initial digestive side effects generally become less intense or resolve entirely during this period. [6,7] By around week 4 at a given dose, a large proportion of mild-to-moderate nausea has resolved without the need for treatment.
Dose increases
Mounjaro is prescribed on a dose-escalation schedule, starting at 2.5 mg and increasing in 2.5 mg steps up to a maximum of 15 mg. [1] Each increase can temporarily bring back side effects—particularly nausea—in a pattern similar to the initial weeks, though often milder. The recurrence rate for nausea at each dose step is around 20–25% of patients. [7] These side effects typically settle again within one to two weeks at the new dose. [6]
After reaching maintenance dose
Once you reach a stable dose and stay on it, side effects continue to decline. Clinical data indicate that the majority of gastrointestinal symptoms resolve after the dose-escalation phase is complete, generally within days to a few weeks of reaching the maintenance dose. [6,7] Some effects can persist longer—sustained appetite reduction and delayed gastric emptying may continue for as long as you are on the medication, since these are part of how the drug works.
Mounjaro Dosage and Side Effects
Mounjaro’s dose-escalation schedule is designed to reduce side effects by giving the body time to adjust. The typical progression is:
2.5 mg for the first four weeks (starting dose), then 5 mg, with further increases in 2.5 mg increments every four weeks as directed by a prescriber. The available doses are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. The maximum dose is 15 mg once weekly. [1]
Side effects are dose-dependent, meaning they are more frequent and sometimes more intense at higher doses. [1,4] For this reason, your prescriber may hold a dose for longer than four weeks before escalating if you are struggling with side effects, or may keep you at a lower maintenance dose if it is effective enough. Rapid dose escalation—increasing the dose faster than recommended—is one of the most common reasons for severe or prolonged side effects. [7]
Serious or Rare Side Effects
While most side effects are mild and temporary, Mounjaro carries warnings for several rarer but more serious adverse events. These require prompt medical attention:
Pancreatitis (inflammation of the pancreas) has been reported in clinical trials. [1,11] Symptoms include severe abdominal pain that may radiate to the back, along with vomiting. If you experience these, stop taking Mounjaro and seek immediate medical advice.
Gallbladder disease Acute gallbladder problems, including gallstones, were reported in about 0.6% of Mounjaro-treated patients in clinical trials. [5,11] Symptoms include sudden pain in the upper right abdomen, nausea and fever.
Severe allergic reactions are possible, though uncommon. Signs include swelling of the face or throat, difficulty breathing and severe rash. Seek emergency medical care if these occur. [1]
Thyroid tumour warning Mounjaro’s prescribing information includes a warning based on animal studies in which tirzepatide caused thyroid C-cell tumours in rats. It is not yet known whether this risk applies to humans. [1] In the US, this is classified as a “boxed warning”—the most serious category the FDA (the regulator) uses. The UK regulator (the MHRA) requires that the risk is disclosed in the product information and that patients are monitored accordingly. Mounjaro should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Contact your doctor if you notice a lump in your neck, hoarseness or difficulty swallowing.
Kidney problems Severe vomiting or diarrhoea can lead to dehydration, which in turn can cause kidney injury. [1] Staying hydrated is important, and you should seek medical advice if you experience persistent vomiting or diarrhoea.
Low blood sugar (hypoglycaemia) This is mainly a risk when Mounjaro is taken alongside insulin or sulfonylureas. [1] Your prescriber may need to adjust the doses of your other diabetes medications.
How to Reduce Mounjaro Side Effects
There are several practical steps you can take to manage side effects, particularly during the first few weeks and after dose increases: [7]
Eat smaller, more frequent meals. Because Mounjaro slows gastric emptying, large meals are more likely to cause nausea and bloating. Eating smaller portions more often can reduce this.
Avoid fatty and greasy foods. High-fat foods take longer to digest, and when combined with Mounjaro’s effect on gastric emptying, they can worsen nausea and discomfort.
Stay hydrated. This is especially important if you are experiencing diarrhoea or vomiting. Dehydration can lead to more serious complications, including kidney problems. Water, herbal teas and clear broths are good choices.
Increase fibre gradually. If you are experiencing constipation, increasing your fibre intake can help—but do so slowly, since a sudden increase in fibre can worsen bloating.
Take the medication consistently. Mounjaro is designed to be taken on the same day each week. Consistent timing helps your body maintain steady drug levels and reduces the likelihood of side effects caused by fluctuating concentrations.
Eat slowly and stop when full. Mounjaro will change your sense of fullness. Paying attention to satiety signals and stopping eating earlier than you might have done before can prevent the discomfort of overeating on a slowed stomach.
If your side effects are severe or persistent beyond a few weeks at the same dose, speak to your prescriber. Options include holding the dose for longer before escalating, reducing the dose, or in some cases trying a different medication.
Who Is More Likely to Experience Side Effects?
Several factors can increase the likelihood or severity of side effects:
Rapid dose escalation is one of the most significant. Increasing the dose faster than the recommended schedule gives the body less time to adapt and is associated with more severe gastrointestinal symptoms. [7]
First-time GLP-1 users tend to experience more side effects than people who have previously taken a GLP-1 medication such as Ozempic or Saxenda. Prior exposure seems to acclimatise the body to this class of drug. [7]
A high-fat diet. Since Mounjaro slows the rate at which food leaves the stomach, diets high in fat—which is already slow to digest—can compound the problem, leading to more nausea and discomfort. [7]
Dehydration. Not drinking enough water can make nausea worse and increases the risk of constipation and, in more serious cases, kidney injury. [1]
Pre-existing digestive sensitivity. People with conditions such as gastroparesis (delayed stomach emptying) or irritable bowel syndrome may find that Mounjaro’s gastrointestinal effects are more pronounced.
Comparing Mounjaro With Other GLP-1 Medications
Mounjaro is part of a growing class of medications that target the GLP-1 receptor. Several other drugs in this class are widely prescribed, and understanding how they relate to each other can be useful.
Wegovy (semaglutide) is a once-weekly injection licensed in the UK specifically for weight management. It targets only the GLP-1 receptor, unlike Mounjaro’s dual GIP/GLP-1 mechanism. [3] In clinical trials, tirzepatide produced greater average weight loss than semaglutide—up to about 22.5% of body weight versus 15–16%. [8] The side-effect profiles are broadly similar, with gastrointestinal symptoms being the most common for both. In January 2026 the MHRA approved a higher 7.2 mg dose of Wegovy, making the UK the first country to authorise it. [9] An oral tablet form of Wegovy has been approved in the US but is not yet available in the UK; an MHRA decision is expected in late 2026.
Rybelsus (oral semaglutide) is a tablet form of semaglutide licensed in the UK for type 2 diabetes. [10] It is taken once daily rather than by weekly injection. Rybelsus is not licensed for weight loss in the UK, and the doses available (up to 14 mg) produce lower semaglutide exposure than the injectable formulations. [10] Its side-effect profile is similar to other GLP-1 medications, with nausea, diarrhoea and vomiting being the most common. For people who prefer tablets over injections but need treatment for type 2 diabetes, Rybelsus may be a suitable alternative.
Ozempic is also semaglutide—the same active ingredient as Wegovy—but it is licensed for type 2 diabetes rather than weight loss. [10] It is sometimes prescribed off-label for weight management. Ozempic’s maximum dose is 2 mg, compared with Wegovy’s standard maximum of 2.4 mg (or the recently approved 7.2 mg dose). [9,10] Importantly, Ozempic and Wegovy are the same drug at different doses and with different licensed indications.
Saxenda (liraglutide) is an older GLP-1 receptor agonist approved for weight loss. It requires daily injections rather than weekly, which many people find less convenient. It also produces less weight loss than tirzepatide or semaglutide: around 6% of body weight in head-to-head comparisons with Wegovy, versus Wegovy’s 16%. [8]
Trulicity (dulaglutide) is a once-weekly GLP-1 injection licensed for type 2 diabetes. It is not licensed for weight loss. Weight loss with Trulicity tends to be modest—typically less than 3% of body weight—compared to Mounjaro and semaglutide-based medications. [8]
All GLP-1 medications share a similar gastrointestinal side-effect profile, since they all slow gastric emptying and suppress appetite through similar pathways. Some patients tolerate one drug in the class better than another, and your prescriber can help determine which is the best fit based on your medical history and how you respond.
Summary
For most people, Mounjaro’s side effects are mild, gastrointestinal in nature, and temporary. They are most likely to occur in the first few weeks of treatment and after each dose increase. The majority resolve within days to a few weeks as the body adapts, and they tend not to recur once a stable maintenance dose is reached. [6,7]
The dose-escalation schedule is specifically designed to minimise these effects, and practical steps—eating smaller meals, avoiding fatty foods, staying hydrated—can make a meaningful difference. Serious side effects are uncommon but do exist, and any severe or persistent symptoms should be discussed with your prescriber.
“If you are considering Mounjaro long-term, you may also want to read about whether GLP-1 medications are suitable as chronic treatments.”
Important note
If you are using this guide as part of care provided through this service, your clinician will consider the most up-to-date evidence and regulatory guidance at the time of assessment and prescribing.
Frequently Asked Questions
How long do Mounjaro's side effects usually last?
Most side effects are temporary. Gastrointestinal symptoms such as nausea, diarrhoea and vomiting typically appear within the first 24–48 hours of an injection and improve over the following weeks. [7] By around week 4 at a given dose, a large proportion of mild-to-moderate symptoms have resolved. [6] Side effects can recur briefly after each dose increase but tend to settle within one to two weeks. [6,7] Once you reach a stable maintenance dose, most side effects diminish significantly.
Does nausea caused by Mounjaro go away?
For most people, yes. Nausea is the most common side effect, affecting roughly 12–20% of trial participants depending on dose, but it is usually mild to moderate and resolves as the body adjusts. [1,4,5] It is most pronounced in the first few days after starting treatment or increasing the dose, and tends to ease within a few weeks. [6,7] If nausea persists or is severe, speak to your prescriber — options include slowing the dose escalation or adjusting your diet.
Are Mounjaro's side effects worse when increasing the dose?
They can be. Side effects are dose-dependent — gastrointestinal symptoms were more common at higher doses in clinical trials. [1,4] Each dose increase can temporarily bring back symptoms such as nausea, with a recurrence rate of around 20–25% at each step. [7] However, these tend to be milder than the initial side effects and usually settle within one to two weeks at the new dose. [6] The dose-escalation schedule (increasing by 2.5 mg every four weeks) is designed to give the body time to adapt. [1]
What is the most common side effect of Mounjaro?
Nausea. In clinical trials, it was reported by roughly 12–20% of participants depending on dose. [1,4,5] Other common gastrointestinal side effects include diarrhoea (12–17%), vomiting (5–9%), constipation (6–8%), decreased appetite (5–11%) and dyspepsia (5–8%). [4,5] These are most frequent during the first few weeks and after dose increases, and most resolve as treatment continues. [6]
Can Mounjaro's side effects last for months?
Most gastrointestinal side effects resolve within days to a few weeks at a stable dose. [6,7] However, some effects can persist for longer. Appetite reduction and delayed gastric emptying may continue for as long as you are taking the medication, since these are part of how the drug works. [3] Rarer but more serious side effects — such as gallbladder disease or pancreatitis — can develop later in treatment and may require medical intervention. [1,11] If any side effect persists beyond a few weeks at the same dose, discuss it with your prescriber.
How can I reduce nausea caused by Mounjaro?
Several practical steps can help. Eating smaller, more frequent meals reduces the burden on a slower stomach. Avoiding fatty and greasy foods is important, since these take longer to digest and can worsen nausea. Staying well hydrated — particularly if you are also experiencing vomiting or diarrhoea — is essential. Eating slowly and stopping as soon as you feel full can also make a difference. [7] If nausea remains troublesome, your prescriber may recommend holding your current dose for longer before increasing it, or may suggest other interventions.
When should I stop taking Mounjaro?
You should not stop taking Mounjaro without consulting your prescriber. However, there are situations where you should seek immediate medical advice: severe abdominal pain that may radiate to the back (a possible sign of pancreatitis), persistent severe vomiting or diarrhoea, signs of a serious allergic reaction such as swelling of the face or throat, or symptoms such as a neck lump or hoarseness that could indicate thyroid problems. [1] Your prescriber may also advise stopping or adjusting treatment if side effects are intolerable despite dose adjustments, or if the medication is not achieving its intended effect.
These answers provide a general overview. For detailed explanations, evidence summaries, and treatment comparisons, see our in-depth guides in the Knowledge Hub.
References
- Mounjaro Summary of Product Characteristics (SmPC). Eli Lilly. Updated January 2026. Available at: medicines.org.uk.
- National Institute for Health and Care Excellence (NICE). Technology Appraisal TA1026: Tirzepatide for managing overweight and obesity. 2024.
- Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovascular Diabetology. 2022;21(1):169.
- Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–155.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205–216.
- Rubino DM, Pedersen SD, Connery L, et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes, Obesity & Metabolism. 2025;27(4):1826–1835.
- Kushner RF, Almandoz JP, Rubino DM. Managing adverse effects of incretin-based medications for obesity. JAMA. 2025.
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine. 2025;393(1):26–36.
- Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes & Endocrinology. 2025;13(11):949–963.
- Andersen A, Knop FK, Vilsbøll T. A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes. Drugs. 2021;81(9):1003–1030.
- Zeng Q, Xu J, Mu X, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Frontiers in Endocrinology. 2023;14:1214334.
About the Author
Dr Blunt is a UK-licensed General Practitioner with an Extended Role in Lifestyle Medicine, and a specialist interest in metabolic health, obesity management, and evidence-based medicine. He has completed accredited training in medical weight management, including the national SCOPE obesity programme.
His writing focuses on translating high-quality research into clear, practical explanations to help readers understand complex topics in obesity, medication safety, and long-term health.
GMC: 7527933
Medical Disclaimer
This information is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition. All content on this website is for general information only and does not replace personalised medical advice. See full Medical Disclaimer.